Related references
Note: Only part of the references are listed.Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with Clopidogrel in acute coronary syndrome
Corinne Frere et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects
Kyoung-Ah Kim et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
A possible new candidate influencing the antiplatelet effect of clopidogrel
Paul A. Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Clopidogrel resistance - More grist for the mill
John A. Cairns et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Betti Giusti et al.
PHARMACOGENETICS AND GENOMICS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease
Ugo Cavallari et al.
BMC MEDICAL GENETICS (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome
Thomas Cuisset et al.
THROMBOSIS RESEARCH (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin
M. Gilard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Quantifying the effect of antiplatelet therapy -: A comparison of the platelet function Analyzer (PFA-100®) and modified thromboelastography (mTEG®) with lightt transmission platelet aggregometry
Seema Agarwal et al.
ANESTHESIOLOGY (2006)
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts
Pierre Savi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Aspirin and clopidogrel resistance: an emerging clinical entity
TH Wang et al.
EUROPEAN HEART JOURNAL (2006)
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
W Hochholzer et al.
CIRCULATION (2005)
Resistance to clopidogrel: A review of the evidence
TA Nguyen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau et al.
CIRCULATION (2004)
Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
P Fontana et al.
CIRCULATION (2003)
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
J Saw et al.
CIRCULATION (2003)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270
ZR Ding et al.
BLOOD (2003)
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction
WC Lau et al.
CIRCULATION (2003)
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
TA Clarke et al.
DRUG METABOLISM AND DISPOSITION (2003)
Structure and stereochemistry of the active metabolite of clopidogrel
JM Pereillo et al.
DRUG METABOLISM AND DISPOSITION (2002)
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
E Braunwald et al.
CIRCULATION (2002)
Genetic and environmental contributions to platelet aggregation - The Framingham Heart Study
CJ O'Donnell et al.
CIRCULATION (2001)